The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Development and validation of prognostic models in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib: A Greek-French collaboration.
Vasilios Karavasilis
No relevant relationships to disclose
Kimon Tzanis
No relevant relationships to disclose
Christina Bamia
No relevant relationships to disclose
Reza-Thierry Elaidi
No relevant relationships to disclose
Efthimios Kostouros
No relevant relationships to disclose
Antonios Visvikis
No relevant relationships to disclose
Dimosthenis-Vasilios Skarlos
No relevant relationships to disclose
Helena Linardou
No relevant relationships to disclose
Evangelia Razis
No relevant relationships to disclose
Michael Chrisofos
No relevant relationships to disclose
Kostas Stravodimos
No relevant relationships to disclose
George Lazaridis
No relevant relationships to disclose
Eleni Timotheadou
No relevant relationships to disclose
Constantinos Hatzimouratidis
No relevant relationships to disclose
Stephane Oudard
Honoraria - Bayer; Novartis; Roche; Sanofi
George Fountzilas
No relevant relationships to disclose
Meletios A. Dimopoulos
No relevant relationships to disclose
Aristotelis Bamias
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Roche
Honoraria - Bayer; Novartis